Targeting p53-MDM2 interactions to identify small molecule inhibitors for cancer therapy: beyond “Failure to rescue”

PO Chukwuemeka, HI Umar, O Iwaloye… - Journal of …, 2022 - Taylor & Francis
PO Chukwuemeka, HI Umar, O Iwaloye, OM Oretade, CB Olowosoke, MO Elabiyi, FO Igbe…
Journal of Biomolecular Structure and Dynamics, 2022Taylor & Francis
At present, disrupting p53-MDM2 interactions through small molecule ligands is a promising
approach to safe treatment and management of human cancer. Tumor cells unlike the
normal cells, are rapidly evolving affecting the efficacy of many approved anti-cancer agents
due to drug resistance. Therefore, identifying a potential anticancer compound is crucial.
Pharmacophore based virtual screening, followed by molecular docking, ADMET evaluation,
and molecular dynamics studies against MDM2 protein was investigated to identify potential …
Abstract
At present, disrupting p53-MDM2 interactions through small molecule ligands is a promising approach to safe treatment and management of human cancer. Tumor cells unlike the normal cells, are rapidly evolving affecting the efficacy of many approved anti-cancer agents due to drug resistance. Therefore, identifying a potential anticancer compound is crucial. Pharmacophore based virtual screening, followed by molecular docking, ADMET evaluation, and molecular dynamics studies against MDM2 protein was investigated to identify potential ligands that may act as inhibitors. The model (AHRR_1) with survival score (4.176) was selected among the top ranked generated Pharmacophore hypothesis. Validation of the model hypothesis by an external dataset of actives and inactive compounds produced significant validation attributes including; AUC = 0.85, BEDROC = 0.56 at α = 20.0, RIE = 8.18, AUAC = 0.88, and EF of 6.2 at the top 2% of the dataset. The model was use for screening the ZINC database, and the top 1375 hits satisfying the model hypothesis were subjected to molecular docking studies to understand the molecular and structural basis of selectivity of compounds for MDM2 protein. A sub-set of 25 compounds with binding energy lower than the reference inhibitors were evaluated for pharmacokinetic properties. Four compounds (ZINC02639178, ZINC06752762, ZINC38933175, and ZINC77969611) showed the most desired pharmacokinetic profile. Lastly, investigation of the dynamic behaviour of leads-protein complexes through MD simulation showed similar RMSD, RMSF, and H-bond occupancy profile compared to a reference inhibitor, suggesting stability throughout the simulation time. However, ZINC02639178 was found to satisfy the molecular enumeration the most compared to the other three leads. It may emerge as potential treatment option after extensive experimental studies.
Communicated by Ramaswamy H. Sarma
Taylor & Francis Online
以上显示的是最相近的搜索结果。 查看全部搜索结果